natgillin/translations-raw huggingface dataset:
The separation zone is generally operated at an overhead pressure of about 100 to about 600 torr, to provide a bottoms temperature in the reaction zone ranging from about 120° C. to about 180° C. The 1,1,2,3-tetrachloropropene product continuously exits the reaction zone through the separation zone, together with hydrogen chloride. 
Postupak prema zahtjevu 1, gdje se postupak dehidrokloriranja provodi uporabom reaktivne destilacijske opreme koja obuhvaća reakcijsku zonu, zonu odvajanja 1 zonu kondenzacije, gdje se 1,1,2,3-tetrakloropropen i klorovodik uklanjanju iz reakcijske zone za dehidrokloriranje putem zone odvajanja i zone kondenzacije.
Distributor power line communication system according to any one of the claims 1-7, characterised in that a second of the at least one gateways (6) is located at a distribution station of the power distribution network. 
Sustav distribucije komunikacije preko elektroenergetske mreže prema bilo kojem zahtjevu 1-7, naznačen time što se drugi od najmanje jednog usmjernika protokola (gateway, 6) nalazi na distribucijskoj stanici elektroenergetsko mreže.
The compound of Claim 28, wherein Y1 is an optionally substituted phenyl, an optionally substituted pyridyl, an optionally substituted thiophenyl, [1,2,3]thiadiazolyl, an optionally substituted isoxazolyl, 1H-pyrazolyl, quinolinyl, imidazolyl, or 2,3-dihydrobenzo[1,4]dioxine. 
Spoj prema zahtjevu 28, naznačen time da Y1 je opcijski supstituiran fenil, opcijski supstituiran piridil, opcijski supstituiran tiofenil, [1,2,3]tiadiazolil, opcijski supstituiran izoksazolil, 1H-pirazolil, kvinolinil, imidazolil, ili 2,3-dihidrobenzo[1,4]dioksin.
the phospholipid complex of silybin with phospholipids as active ingredients, in admixture with suitable excipients. 
fosfolipidni kompleks silbina s fosfolipidima kao aktivnim tvarima, u smjesi s pogodnim ekscipijenioma.
Solubilisation can be achieved by adding a detergent such as SDS, preferably to give a final concentration of between 4 and 4.5%. 
Otapanje se može postići dodavanjem deterdženta kao što je SDS, pogodno da se dade konačna koncentracija od između 4 i 5%.
W is a group of formula (Wa1) or (Wa2) as defined in Claim 2, or 
W je skupina formule (W.,) ili (W.2) definirana kao u zahtjevu 2, ili
is -C1-4 alkylene-CH(O) or -C1-5 alkylene-NH-, wherein the -NH- group is part of a protein carrier; wherein the protein carrier is a protein defined in claim 15 and wherein at least 80% of the monosaccharide units of the saccharide have blocking groups as defined in claims 1-4. 
R* je -C,u alkilen-CH(O) ili -C,.5 alkilen-NH-, gdje je skupina dio proteinskog nosača; gdje je proteinski nosač protein u skladu s patentnim zahtjevom 15 te gdje najmanje 80% monosaharidnih jedinica u saharidu imaju blokirajuće skupine u skladu s patentnim zahtjevima 1-4.
Fig. 3 shows the enclosing unit in its opened state. 
Slika 3 prikazuje jedinicu za zatvaranje u svojem otvorenom položaju.
A process according to claim 1, wherein, in the event said nitrite is potassium nitrite, the crown ether is the 18-crown-6 ether, in the event said nitrite is sodium nitrite, said crown ether is 15-crown-3-ether. 
Postupak u skladu s bilo kojim patentnim zahtjevom od 1 do 3, naznačen time što krunasti eter je 18-kruna-6-eter u slučaju upotrebe kalijevog nitrita, a 15-kruna-5-eter u slučaju upotrebe natrijevog nitrita.
The pest control device according to claim 10, wherein the colorant comprises one or more of: patent blue, brilliant blue, CI direct red 254, Tartazine yellow, Azorubine and Alizarin, annato, B-carotene, carmine, carmoisine, copper-clorophyllin, curcumin, enocianin, lutein, or ponceau 4R. 
Uređaj za suzbijanje štetočina prema bilo kojem od patentnih zahtjeva od 3 do 5, naznačen time da se bojilo sastoji od jednog od sljedećih sastojaka: patent plave, brilijant plave, CI izravno crvene 254, Tartazine žute, azorubina i alizarina, anato boje, beta karotena, karmina, karmoizina, klorofilina, kurkumina, enocijanina, luteina, košinel crvene A.
The process of paragraph 1, wherein said first solvent is selected from the group consisting of xylene, N-methylpyrrolidinone, Dimethylsulfoxide, diphenyl ether, Dimethylacetamide, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeno prvo otapalo se bira iz skupine koju čine ksilen, V-metilpirolidinon, dimetil-sulfoksid, difenil-eter, dimetilacetamid, te smjese 2 ili više njih.
Suitable cosolvents are in particular ethanol, glycerol, propylene glycol and polyethylene glycol or 1,3-butanediol. 
Prikladna ko-otapala su posebno etanol, glicerol, propilen glikol i polietilen glikol ili 1,3-butandiol.
A polynucleotide comprising a polynucleotide encoding the light chain and the heavy chain of the antibody of claim 1 or 2. 
3. - Polinukleotid naznačen time da sadrži polinukleotid koji kodira lagani lanac i teški lanac protutijela prema zahtjevu 1 ili 2.
The apparatus of claim 1, wherein the energy delivery element is configured to have a length of about 1 cm to about 3 cm. 
Aparat prema zahtjevu 1, naznačen time, što je element za isporuku energije konfiguriran da bude dug od oko 1 cm do oko 3 cm.
A paper product comprising a co-processed microfibrillated cellulose and inorganic particulate material composition, wherein the paper product has: a first tensile strength greater than a second tensile strength of the paper product devoid of the co-processed microfibrillated cellulose and inorganic particulate material composition; and/or ii) a first tear strength greater than a second tear strength of the paper product devoid of the co-processed microfibrillated cellulose and inorganic particulate material composition; and/or 
Papirni proizvod, koji sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala, naznačen time što papirni proizvod ima: a. prvu vlačnu čvrstoću veću od druge vlačne čvrstoće papirnog proizvoda koji ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala; i/ili b. prvu čvrstoću na kidanje veću od druge čvrstoće na kidanje papirnog proizvoda koji ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala; i/ili
The process of claim 1, wherein the concentration of H2SO4 is from about 10 g/L to about 200 g/L. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se koncentracija H,SO, kreće od 10 g/l do 200 g/l.
Embodiment 43: The compound according to embodiment 39, wherein the compound is 3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; 
Spoj prema zahtjevu 7, naznačen time, da je to: 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((S)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)- amid, ili njegova farmaceutski prihvatljiva sol.
The process of claim 6 wherein said organic acid is acetic acid or naphthenic acid. 
Sastav prema zahtjevu 8, naznačen time da je organska kiselina octena kiselina ili naftenska kiselina.
grooves in a support ring of the capsule holder 23 
utori na potpornom prstenu držača čahure 23
The method of claim 5, wherein in Formula (I′), R1 is a hydrogen atom, and R2 is a hydrogen atom; a hydroxy group; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy group; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (T') iz patentnog zahtjeva 5 za njegovu primjenu prema patentnom zahtjevu 5, gdje u formuli (T), R' je atom vodika, i R* je atom vodika; hidroksi grupa; ravna ili razgranata C,-C4 alkil grupa; ravna ili razgranata C;- Cs alkoksi grupa; ili ravna ili razgranata C;-Cz tioalkil grupa.
An isolated antigen binding protein of claim 1, 2 or 3 wherein said antigen binding protein has at least one property selected from the group consisting of: reducing human IL-23 activity; reducing production of a proinflammatory cytokine; 
Protein koji veže antigen iz bilo kojeg od patentnih zahtjeva 1-5, pri čemu navedeni protein koji veže antigen ima najmanje jedno svojstvo odabrano iz grupe koja se sastoji od: a) < smanjivanja aktivnosti ljudskog IL-23 u određivanju metodom STAT-luciferaze; b) smanjivanje stvaranja proupalnih citokina;
Compound of formula I: and pharmaceutically acceptable salts thereof, wherein: 
Spoj formule I: HR P20181086 T1 fenilaminoakarbonila, CH>R., gdje
The pressure fluid inlet 7, extending through a side wall, i.e. 
Ulaz za tlačni medij 7, koji se proteže kroz bočnu stijenku, tj.
Packaging unit according to claim 3 or 4, wherein the label is attached to the top surface such that air cushions are formed between the label and the cover part. 
Jedinica za pakiranje prema zahtjevu 3 ili 4, naznačena time da je naljepnica učvršćena na gornju površinu tako da između naljepnice i pokrovnog dijela nastaju zračni jastuci.
METHOD OF PRODUCING A POLYPEPTIDE OR VIRUS OF INTEREST IN A CONTINUOUS CELL CULTURE 
Postupak proizvodnje polipeptida u kontinuiranoj staničnoj kulturi, navedeni postupak sadrži:
is not a candidate to receive treatment with an immunomodulator if the biological sample is positive for a JCV antibody; or 
(ii) nije kandidat da primi liječenje imunomodulatorom ako je biološki uzorak pozitivan na protutijelo protiv JCV; ili
A soft chewable veterinary composition for use according to claim 31, wherein the parasite is a nematode, a cestode, a trematode or a filarial parasite. 
Mekani veterinarski pripravak za žvakanje za uporabu prema zahtjevu 33, naznačen time, da se kod parazita radi o nematodu, cestodu, trematodu ili filarijalnom parazitu.
a host cell of claim 13. A polypeptide of any of claims 1-3, a polypeptide dimer of claim 4 or claim 5, a fusion protein of claim 6 or claim 7, a fusion protein dimer of any of claims 8-10, a nucleic acid of claim 11, a vector of claim 12, or a cell of claim 13, for use in: 
Polipeptid prema bilo kojem od zahtjeva 1-3, dimerni polipeptid prema zahtjevu 4, fuzijski protein prema zahtjevu 5 ili zahtjevu 6, dimerni fuzijski protein prema zahtjevu 7 ili zahtjevu 8, nukleinska kiselina prema zahtjevu 9, vektor prema zahtjevu 10, ili stanica prema zahtjevu 11, naznačeni time da su za uporabu za:
The method of Claim 1, wherein the amount of G-CSF in the buffered G-CSF-formulation of step (a) is in the range of from 0.1 mg/ml to 8.0 mg/ml, preferably of from 0.25 mg/ml to 6.5 mg/ml. 
Postupak prema zahtjevu 1, naznačen time, da je količina od G-CSF u puferiranom G-CSF-sastavu iz koraka (a) u rasponu od 0,25 mg/ml do 6,5 mg/ml.
washing said SCA with PBS; and re-suspending said SCA in water or 2% mannitol. 
pranje navedenog SIA s PBS-om; i resuspendiranje navedenog SIA u PBS-u.
After phase separation the organic phase is 3 times washed with brine and then evaporated. 
Nakon odvajanja faza organska faza se ispere tri puta s otopinom soli 1 zatim se evaporira.
The plant product according to claim 6, wherein the plant product is a wort composition prepared using the barley plant, or part thereof, wherein the barley plant carries the mutation in the gene encoding methionine-S-methyltransferase (MMT) that causes a total loss of MMT function, or using a malt composition prepared from said barley plant or part thereof, or mixtures thereof. 
Sastav sladovine pripravljem pomoću ječma, ili njegovog dijela, sukladno bilo kojem od zahtjeva 6 do 9, ili uporabom spoja pripravljenog od navedenog ječma ili njegovog dijela, ili njihovih mješavina, pri čemu spoj sladovine sadrži manje od 20 ppb SMM.
wherein the variables are as defined in claim 1; reacting an intermediate of formula (II) with an appropriate carboxaldehyde of formula (VI) with the formation of a compound of formula (I), wherein t is 1, herein referred to as compounds of formula (I-c), 
ROB pri čemu su varijable kako je definirano u zahtjevul; d) reakciju međuprodukta formule (II) odgovarajućim karboksaldehidom formule (VI) uz stvaranje spoja formule (I), pri čemu t je 1, ovdje se nazivaju spojevi formule (I-c), s =
to 5 wt%, preferably 0.5 to 3 wt.% of polyols other than hexylene glycol. 
0,1 do 5 težinskih postotaka, poželjno 0,5 do 3 težinskih postotaka bilo kojeg poliola osim heksilen glikola.
The granules were dried in a Glatt 3/5 fluid bed drier, screened by Comil into a Pharmatec 10 Litre bin blender and then blended with any lactose anhydrous given in the formula plus the remainder of the croscarmellose sodium over 15 minutes at 17 rpm. 
Granule se osuše u Glatt 3/5 sušilici s fluidnim slojem, prosiju pomoću Comil-a u Pharmatec 10-litrenu miješalicu s posudom 1 zatim miješaju s bezvodnom laktozom danom u formuli plus ostatkom kroskarameloza natrija tijekom 15 minuta pri 17 okr/min.
Such a synergistic action of the OMB fertilizer is made possible by the simultaneous penetration and action of the poly-phenolic, chinoidic and other groups on the cells of the plants exposed to the fertilizer. 
Takav neočekivan i izvanredno poboljšani učinak gnojiva moguć je zbog istovremenog prodiranja i djelovanja polifenolnih, kinoidnih i drugih skupina na stanice gnojenih biljaka.
The method is characterized in that the administration takes place by parenteral administration (injection or infusion). 
Postupak jeo karakteriziran time da je primjena parenteralna primjena (injekcijom ili infuzijom).
In one embodiment, the cancer is selected from the group consisting of tumors of the central nervous system, head and neck cancer, lung cancer, such as NSCLC, breast cancer, specifically triple-negative breast cancer, esophageal cancer, gastric or stomach cancer, liver and biliary cancer, pancreatic cancer, colorectal cancer, bladder cancer, kidney cancer, prostate cancer, endometrial cancer, ovarian cancer, malignant melanoma, sarcoma, tumors of unknown primary origin, bone marrow cancer, acute lymphoblastic leukemia, chronic lymphoblastic leukemia and non-Hodgkin lymphoma, skin cancer, glioma, cancer of the brain, uterus, acute myeloid leukemia and rectum. In one embodiment the cancer is pancreatic cancer. 
Konjugat protutijela s lijekom za uporabu prema zahtjevu 13, naznačen time, da je rak odabran iz skupine koju čine tumori centralnog nervnog sustava, rak glave i vrata, rak pluća, kao što je primjerice NSCLC, rak dojke, osobito trostruko negativan rak dojke, rak jednjaka, gastrički rak ili rak želudca, rak jetre 1 žuči, rak pankreasa, kolorektalni rak, rak mjehura, rak bubrega, rak prostate, rak endometrija, rak jajnika, maligni melanom, sarkom, tumori nepoznatog primarnog podrijetla, rak koštane srži, akutna limfoblastna leukemija, AML, kronična limfoblastna leukemija i ne-Hodgkin-limfom, rak kože, gliom, rak mozga, uterusa i rektuma.
optionally other components. 
(d) izborno druge komponente.
Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells 
SPOJEVI I POSTUPCI SMANJIVANJA NOVAČENJA I/ILI SELJENJA POLIMORFONUKLEARNIH STANICA
Paragraph 1. A process for the preparation of a compound of formula I, 
PATENTNI ZAHTJEVI 1. = Postupak za dobivanje spoja formule I, pri čemu:
The compounds of formula I according to any of claims 1-3, wherein R3 is selected from the groups consisting of alkenyl, aryl, heteroaryl, cycloalkyl and heterocyclyl, each of which may be unsubstituted or substituted by one or more substituents, The compound of formula I according to any of claims 1-4 wherein R1 is alkynyl or alkoxy; 
alkenil, heteroaril, cikloalkil i heterociklil, gdje alkenil, heteroarili, cikloalkil ili heterociklil mogu biti nesupstituirani ili supstituirani s jednim ili više supstituenata, koje se bira iz skupine koju čine: -H, alkil, alkenil, alkoksi, halogen, -OH, -N3, triflurometil, -alkil-aril, -O-alkil-aril, -CO-aril, aril, heterociklil, heteroaril,-CO-heteroaril, -CO-O-alkil, -CO-N-alkil, -CO-N-aril, ili njegovi farmaceutski prihvatljivi solvati, soli, N-oksidi ili stereoizomeri, ili njihove kombinacije.
Method according to any one of the preceding claims, wherein the feed comprises a hydrocarbon selected from the group consisting of ethane, propane, butanes, naphthas, kerosenes, atmospheric gasoils, vacuum gasoils, heavy distillates, hydrogenated gasoils, gas condensates and mixtures thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da opskrbni materijal uključuje ugljikovodik odabran iz skupine koja sadrži etan, propan, butane, nafie, kerozine, atmosferska plinovita ulja, vakuumska plinovita ulja, teške distilatore, hidrizirana plinovita ulja, plinovite kondenzate i smjese navedenih.
Tolerance of the strip of the invention 
Odstupanje trake prema izumu
The Staphylococcus aureus vaccine of claim 12, wherein said protein is Pseudomonas aeruginosa Exotoin, or Staphylococcus aureus alpha hemolysin, or Staphylococcus aureus clumping factor A. 
Cjepivo protiv bakterije Staphylococcus aureus u skladu s patentnim zahtjevom 12, naznačeno time što je navedeni protein egzotoksin iz bakterije Pseudomonas aeruginosa, ili alfa hemolizin iz bakterije Staphylococcus aureus, ili aglutinacijski čimbenik A iz bakterije Staphylococcus aureus.
Preferably, D-H is a biopolymer selected from the group of biopolymers consisting of proteins, polypeptides, oligonucleotides, and peptide nucleic acids. 
Predlijek prema bilo kojem od zahtjeva 1 do 16, naznačen time, da D-H je biopolimer odabran iz skupine koja se sastoji od proteina, polipeptida, oligonukleotida i peptidnih nukleinskih kiselina.
V is C1-6 alkylene which may be substituted with oxo (=O). 
V je C,_ alkilen koji može biti supstituiran s okso (=0).
The thread profile lines 518a-f extend through troughs 512 and result in a series of lines that intersect the center 526 of the radius of curvature 525. 
Sustav u skladu s patentnim zahtjevom 1, naznačen time, da navoj profila ima profilne linije (618) koje se sijeku u centru (626) polumjera zakrivljenosti lučnog segmenta (625).
The dual chamber prefillable syringe according to Claim 4, wherein after the guide plate surmounts the first protrusion by rotating the plunger rod in accordance with the female screw portion and the male screw portion, the screwing between the male screw portion and the female screw portion is released. The dual chamber prefillable syringe according to Claim 5, further comprising: 
Å prica sa dvostrukom komorom koja se može unaprijed napuniti u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time, da se zavrtanje između muškog dijela navoja i ženskog dijela navoja aktivira nakon što je ploča za vođenje prešla prvu izbočinu, zakretanjem drške klipa sukladno ženskom dijelu navoja 1 muškom dijelu navoja.
Use according to claim 19, wherein the amount of C12 to C36 aliphatic alcohol or acid is at least 5 %, more preferred at least 10 % (by wt), more preferred at least 15 % (by wt) and most preferred 20 % to 25 % (by wt) of the matrix formulation. 
Uporaba prema zahtjevu 13, gdje je količina C12 to C36 alifatskog alkohola ili kiseline barem 5%, poželjno barem 10% (težinski), poželjnije barem 15% (težinski) i najpoželjnije 20% do 25% (težinski) formulacije matriksa.
The compound for use according to claim 5 or 6, wherein the second RNA viral polymerase is selected from the group consisting of adenovirus, influenza A, influenza B, parainfluenza, respiratory syncytial, rhinovirus, Junin, Pichinde, Rift Valley Fever, Dengue Fever, measles, Yellow Fever, tacaribe, Venezuelan equine encephalitis, West Nile, and SARS-CoV viral polymerases. 
Spoj za uporabu sukladno zahtjevu 12, pri čemu je virusna RNK polimeraza polimeraza odabrana iz skupine koju čine virusne polimeraze virusa Denga groznice, virusa influence A, virusa influence B, Junin virusa, virusa ospica, parainfluenca virusa, Pichinde virusa, Punta Toro virusa, respiratornog sincicijalnog virusa, rinovirusa, virusa groznice doline Rift, SARS virusa, Takaribe virusa, virusa venecuelanskog konjskog encefalitisa, virusa Zapadnog Nila, i virusa žute groznice
• two movable side guides (14,15,114,115,314) for the curtain, wherein either: 
* dvije pokretne bočne vodilice (14, 15, 114, 115,314) za zavjese, pri čemu:
The aqueous slurry according to claim 3, wherein mixtures of monoalkoxylated phosphoric acid of the Formula (I) having from 5 to 15 units of propylene oxide are present in the esterification. 
Vodena suspenzija u skladu s patentnim zahtjevom 3 ili 4, naznačena time što se upotrebljavaju smjese monoalkoksiliranih fosfornih kiselina formule (I) s 5 do 15 propilen-oksidnih jedinica.
Thus, A2A receptor antagonists show great potential as future drugs for long-term medication of PD patients, since they do not only reverse the motor impairment but also can slow down or stop the progress of the disease by promoting cell survival. 
Prema tome, antagonisti A»,-receptora pokazuju veliki potencijal kao budući lijekovi koji bi se mogli primjenjivati u dugotrajnom liječenju pacijenata oboljelih od PB, budući da ne samo da omogućavaju reverzibilno poboljšanje motorike, već mogu i usporiti ili u potpunosti zaustaviti napredak bolesti produžujući život stanice.
an Evolved Universal Terrestrial Radio Access Network (E-UTRAN) technology, 
Evolved Universal Terrestrial Radio Access Network), - Tehnologija dugoročne evolucije (engl.
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier or excipient. 
Farmaceutski sastav, naznačen time, da sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 4i farmaceutski prihvatljiv nosač ili ekscipijent.
The aqueous pharmaceutical suspension according to claim 3, wherein the butylparaben, or sodium butylparaben is, by weight/volume (g/100 mL), 0.014% to 0.020%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što butilparaben ili natrij- butilparaben iznosi, težinski/volumno (£/100 ml), otprilike 0,014 % do otprilike 0,020 %.
from 0 to 12% of quartz, silica, expanded silica, silica fume or any other sedimentary, metamorphic or magmatic rocks or industrial mineral derivatives having a silicon content; and 
- < od 0 do 12% kvarca, silike, proširene silike, fine silike ili bilo kojih drugih sedimentnih, metamorfnih ili magmatskih stijena, ili industrijskih derivata minerala sa visokim sadržajem silikona; te -
A compound of formula (I) wherein n is 0 to 4; 
Spoj formule (I) [image] naznačen time, da n je 0 do 4;
The titanium atrane catalysts of the present invention may be synthesized using the following steps: First, an alcohol solution is prepared by adding a titanium (IV) alkoxide to a first solvent. 
Postupak za pripravu katalizatora titanij atrana, naznačen time, da se sastoji od: (a) stupanja u vezu otopine koja sadrži spoj titanij (IV) alkoksida 1 prvo otapalo s organskom kiselinom;
a hopper (5) placed inside the vessel (2) and tapering to a discharge outlet in direction of the vessel opened end (4), 
- lijevak (5), koji se sužava prema izlazu za pražnjenje (6), gdje navedeni lijevak se stavlja u posudu (2), i
Method according to claim 3, wherein component d) is selected from the group consisting of sulphated amino acids and derivatives thereof, 1-methionine, 1-cysteine, 1-cystine, taurine, 4-thiazolidinecarboxylic acid and methylsulphonylmethane. 
Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time, da je sastojak d) odabran između aminokiselina koje sadrže sumpornu grupu i njihovih derivata, 1-metionina, 1-cisteina, 1-cistina, taurina, 4-tiazilidinkarboksilne kiseline i/ili metilsulfonilmetana.
selected from the group consisting of ≥ 30 minutes, ≥ 60 minutes, ≥ 90 minutes, ≥ 120 minutes, ≥ 150 minutes, ≥ 180 minutes, ≥ 210 minutes, and ≥ 240 minutes. 
odabranu vrijednost iz skupine koju čine: ≥ 30 minuta, ≥ 60 minuta, ≥ 90 minuta, ≥ 120 minuta, ≥ 150 minuta, ≥ 180 minuta, ≥ 210 minuta i ≥ 240 minuta.
Packaging assembly for pharmaceutical composition including pimobendan 
FARMACEUTSKI SASTAV KOJI SADRŽI PIMOBENDAN HR P20140900 T1
The reaction mixture was poured into saturated aqueous sodium sulphite solution. (200 ml) and water (200 ml) added. 
Rcakcijska smjesa se ulije u zasićenu vodenu otopinu natrij sulfita (200 ml) i doda sc voda (200 ml).